SRC and non-small cell lung carcinoma: Cells treated with the potent SRC inhibitor saracatinib and cells in the control group were subjected to transcriptome sequencing for the sake of understanding the downstream genes and pathways of SRC in KRAS-mutant NSCLC cells.